Company profile
FULCRUM THERAPEUTICS, INC.
NASDAQ:FULCBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| POCIREDIR | phase2 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04003974 | phase2 | completed | 2019-08-09 | 2021-01-28 | Fulcrum Therapeutics | Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) |
| NCT05397470 | phase3 | terminated | 2022-06-16 | 2024-11-19 | Fulcrum Therapeutics | Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) |
| NCT04264442 | phase2 | terminated | 2020-02-13 | 2024-11-07 | Fulcrum Therapeutics | Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE) |
| NCT04004000 | phase2 | terminated | 2019-08-23 | 2024-10-31 | Fulcrum Therapeutics | Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension |
| NCT04511819 | phase3 | terminated | 2020-08-28 | 2021-03-31 | Fulcrum Therapeutics | Losmapimod Safety and Efficacy in COVID-19 |
FDA applications (0)
No records yet.